Related Experiment Videos
Reversing coronary atherosclerosis. How to put findings of recent trials to practical use
1University of Michigan Medical School, Ann Arbor.
Abstract:
The value of aggressively modifying lipid levels in patients who have established coronary artery disease has been clarified by recent studies. Diet or drug programs that lower low-density lipoprotein (LDL) cholesterol levels to 100 mg/dL or less may halt disease progression and reverse preexisting arterial plaques. The safety of these programs has been demonstrated, and trends toward improved survival time have been observed in the larger studies. Improvement in anginal control and clinical stability, with fewer required coronary revascularization procedures, are also noted with this therapy. All patients with established coronary artery disease should undergo fasting lipid profiles, including measurements of LDL and high-density lipoprotein cholesterol fractions. Dietary and drug therapy if necessary should be offered to achieve the target LDL cholesterol level. Ongoing studies will further clarify the role of newer lipid-lowering agents and potential benefits of noninvasive monitoring techniques in patients with atherosclerosis.
Insights
Aggressively lowering low-density lipoprotein (LDL) cholesterol to 100 mg/dL or less can halt coronary artery disease progression and reverse plaques. This approach improves survival and clinical stability, making it a recommended therapy for established cardiovascular disease.
Area of Science:
- Cardiology
- Lipidology
- Preventive Medicine
Background:
- Established coronary artery disease (CAD) necessitates effective management strategies.
- Recent studies highlight the impact of lipid modification on CAD.
- Understanding the benefits of aggressive lipid lowering is crucial for patient outcomes.
Purpose of the Study:
- To clarify the value of aggressively modifying lipid levels in patients with established CAD.
- To assess the impact of LDL cholesterol reduction on disease progression and plaque reversal.
- To evaluate the safety and survival benefits of lipid-lowering therapies.
Main Methods:
- Review of recent studies on lipid modification in CAD patients.
- Analysis of dietary and drug programs targeting LDL cholesterol reduction.
- Assessment of clinical outcomes including disease progression, plaque reversal, survival, and revascularization rates.
Main Results:
- Lipid-lowering programs achieving LDL cholesterol ≤100 mg/dL can halt CAD progression.
- These interventions may reverse preexisting arterial plaques.
- Improved survival, anginal control, and reduced need for revascularization procedures are observed.
Conclusions:
- Aggressive lipid modification is valuable in established CAD.
- Fasting lipid profiles are recommended for all CAD patients.
- Therapeutic interventions should aim for target LDL cholesterol levels, with ongoing research into new agents and monitoring.